Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | F13A1 | P00488 | 1/20 | 0.68 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | ESRRB | O95718 | 3/20 | 0.54 |
| ▸ | ESRRG | P62508 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9127807 | 0.92 | GLA (0.62) | KDM4EF13A1ABCG2GLAKMT2A | |
| SCHEMBL20961904 | 0.85 | KMT2A (0.59) | GLAKMT2ASMN1; SMN2NPC1GAA | |
| SCHEMBL580001 | 0.84 | GLA (0.72) | KDM4EF13A1ABCG2GLAKMT2A | |
| SCHEMBL4322629 | 0.84 | GLA (0.77) | KDM4EGLAKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL2021427 | 0.84 | FPR2 (0.58) | KDM4EGLAKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL14515857 | 0.84 | ESRRG (0.55) | KDM4EF13A1GLAKMT2AESRRG | |
| SCHEMBL8700358 | 0.84 | CYP1A2 (0.63) | GLAKMT2ASMN1; SMN2NPC1GAA | |
| SCHEMBL2095490 | 0.83 | TAAR1 (0.69) | SMN1; SMN2NPC1GAARAB9AMAPT | |
| SCHEMBL100146 | 0.83 | KDM4E (0.60) | KDM4EF13A1ABCG2GLAKMT2A | |
| SCHEMBL30439339 | 0.82 | CA2 (0.58) | KDM4EF13A1ABCG2TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-02-05 | — | — | US | disclosed |
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-21 | — | — | US | disclosed |
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-21 | — | — | US | disclosed |
| WO-2015027324-A1 | MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-03-05 | — | — | WO | disclosed |
| EP-2208727-A1 | Diaryl ethers as opioid receptor antagonist | Eli Lilly & Company (US) | 2010-07-21 | — | — | EP | disclosed |
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7531557-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| CN-1305852-C | Diaryl ethers as opioid receptor antagonists | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| EP-1562595-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | MAOB, MAOA, COMT | KDM4E 592/4885F13A1 2840/4885ABCG2 117/4885 |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | KDM4E 595/4885F13A1 1933/4885ABCG2 2657/4885 |
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | MAOB, MAOA, COMT | KDM4E 592/4885F13A1 2840/4885ABCG2 117/4885 |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | KDM4E 634/4885F13A1 1935/4885ABCG2 2709/4885 |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | OPRM1, OPRL1, OPRD1 | KDM4E 608/4885F13A1 1979/4885ABCG2 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.